About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Texas | 1,129 Studies

Clinical Trials LymphomaTexas

Lymphoma Clinical Trials in Texas

Find 1,129 clinical trials for lymphoma near Texas. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Texas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 321-340 of 1,129 trials

TerminatedAn Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaThe purpose of this study is to assess overall response rate \[ORR, including complete response (CR) and partial response (PR)\], of daratumumab in participants with non-Hodgkin's…NCT02413489·Duarte, California and 34 others Active not recruitingA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT05578976·Tucson, Arizona and 330 others

PreviousPage 17 of 57Next

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedStudy of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell LymphomaThis study has two phases, a dose escalation phase and a dose expansion phase.NCT01402440·Duarte, California and 23 others

TerminatedCluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell LymphomaThe purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody…NCT03287817·Duarte, California and 10 others

TerminatedStudy of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaThis is a Phase 1, nonrandomized, open-label, dose-escalation study of 3-hour IV infusions of RH-1 administered to patients with advanced solid tumors or non-Hodgkin's lymphoma…NCT00558727·Aurora, Colorado and 3 others

TerminatedT-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINEPatients are being asked to participate in this study because they have a cancer in their blood (such as leukemia or lymphoma) or myelodysplastic/myeloproliferative (pre-leukemia).NCT00578461·Houston, Texas

Terminated506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell LymphomaDrugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00005982·Houston, Texas

CompletedOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in…NCT03233204·Birmingham, Alabama and 112 others

CompletedA Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or LymphomasDS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is…NCT01588678·San Antonio, Texas

RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have…NCT05254743·Anaheim, California and 142 others

CompletedIMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaThe purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia…NCT01534715·Boston, Massachusetts and 6 others

CompletedMLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- VincristineThis is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell…NCT01397825·Tucson, Arizona and 24 others

Active not recruitingA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLThis study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated…NCT02972840·Tucson, Arizona and 227 others

CompletedA Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaThis study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide…NCT02733042·Gilbert, Arizona and 65 others

TerminatedA Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.NCT03743246·Duarte, California and 18 others

RecruitingSample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin…NCT07750886·Austin, Texas

Active not recruitingStudy of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantThis study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa…NCT03301168·Los Angeles, California and 9 others

TerminatedA Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1…NCT05403450·Duarte, California and 45 others

Active not recruitingPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLThis is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323).NCT03960840·Los Angeles, California and 36 others

CompletedA Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesThis is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of…NCT03310619·Duarte, California and 8 others

Other Conditions in Texas

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia